Claims for Patent: 7,951,797

Summary for Patent: 7,951,797

Title:	Substituted diazepan orexin receptor antagonists
Abstract:	The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Inventor(s):	Breslin; Michael J. (Drexel Hill, PA), Coleman; Paul J. (Wallingford, PA), Cox; Christopher D. (Harleysville, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	11/998,812
Patent Claims:	1. A compound which is: 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole; or a pharmaceutically acceptable salt thereof. 2. A compound which is 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole. 3. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound which is: 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole; or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole. 5. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound which is: 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole; or a pharmaceutically acceptable salt thereof. 6. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole. 7. A compound which is 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl}-1,3-benzoxazole in the form of a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1- ,4-diazepan-1-yl }-1,3-benzoxazole in the form of a pharmaceutically acceptable salt thereof. 9. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound 5-chloro-2-{(5R)-5-methyl-4-[methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4- -diazepan-1-yl }-1,3-benzoxazole in the form of a pharmaceutically acceptable salt thereof.